1
|
De Lay NR, Verma N, Sinha D, Garrett A, Osterberg MK, Reiling S, Porter D, Giedroc DP, Winkler ME. The five homologous CiaR-controlled Ccn sRNAs of Streptococcus pneumoniae modulate Zn-resistance. bioRxiv 2024:2023.11.07.565944. [PMID: 37986909 PMCID: PMC10659304 DOI: 10.1101/2023.11.07.565944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2023]
Abstract
Zinc is a vital transition metal for Streptococcus pneumoniae, but is deadly at high concentrations. In S. pneumoniae, elevated intracellular free Zn levels result in mis-metallation of key Mn-dependent metabolic and superoxide detoxifying enzymes resulting in Zn intoxication. Here, we report our identification and characterization of the function of the five homologous, CiaRH-regulated Ccn sRNAs in controlling S. pneumoniae virulence and metal homeostasis. We show that deletion of all five ccn genes (ccnA, ccnB, ccnC, ccnD, and ccnE) from S. pneumoniae strains D39 (serotype 2) and TIGR4 (serotype 4) causes Zn hypersensitivity and an attenuation of virulence in a murine invasive pneumonia model. We provide evidence that bioavailable Zn disproportionately increases in S. pneumoniae strains lacking the five ccn genes. Consistent with a response to Zn intoxication or relatively high intracellular free Zn levels, expression of genes encoding the CzcD Zn exporter and the Mn-independent ribonucleotide reductase, NrdD-NrdG, were increased in the ΔccnABCDE mutant relative to its isogenic ccn+ parent strain. The growth inhibition by Zn that occurs as the result of loss of the ccn genes is rescued by supplementation with Mn or Oxyrase™, a reagent that removes dissolved oxygen. Lastly, we found that the Zn-dependent growth inhibition of the ΔccnABCDE strain was not altered by deletion of sodA, whereas the ccn+ ΔsodA strain phenocopied the ΔccnABCDE strain. Overall, our results indicate that the Ccn sRNAs have a crucial role in preventing Zn intoxication in S. pneumoniae.
Collapse
Affiliation(s)
- Nicholas R. De Lay
- Department of Microbiology and Molecular Genetics, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA
- MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX 77030, USA
| | - Nidhi Verma
- Department of Microbiology and Molecular Genetics, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA
| | - Dhriti Sinha
- Department of Microbiology and Molecular Genetics, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA
| | - Abigail Garrett
- Department of Biology, Indiana University Bloomington, Bloomington, Indiana 47405
| | | | - Spencer Reiling
- Department of Microbiology and Molecular Genetics, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA
| | - Daisy Porter
- Department of Microbiology and Molecular Genetics, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA
| | - David P. Giedroc
- Department of Chemistry, Indiana University, Bloomington, Bloomington, Indiana 47405
| | - Malcolm E. Winkler
- Department of Biology, Indiana University Bloomington, Bloomington, Indiana 47405
| |
Collapse
|
2
|
Evans SM, Ivanova K, Rome R, Cossio D, Pilgrim C, Zalcberg J, Antill Y, Blake L, Du Guesclin A, Garrett A, Giffard D, Golobic N, Moir D, Parikh S, Parisi A, Sanday K, Shadbolt C, Smith M, Te Marvelde L, Williams K. Registry-derived stage (RD-Stage) for capturing cancer stage at diagnosis for endometrial cancer. BMC Cancer 2023; 23:1222. [PMID: 38087227 PMCID: PMC10714535 DOI: 10.1186/s12885-023-11615-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2023] [Accepted: 11/06/2023] [Indexed: 12/18/2023] Open
Abstract
BACKGROUND Capture of cancer stage at diagnosis is important yet poorly reported by health services to population-based cancer registries. In this paper we describe current completeness of stage information for endometrial cancer available in Australian cancer registries; and develop and validate a set of rules to enable cancer registry medical coders to calculate stage using data available to them (registry-derived stage or 'RD-Stage'). METHODOLOGY Rules for deriving RD-stage (Endometrial carcinoma) were developed using the American Joint Commission on Cancer (AJCC) TNM (tumour, nodes, metastasis) Staging System (8th Edition). An expert working group comprising cancer specialists responsible for delivering cancer care, epidemiologists and medical coders reviewed and endorsed the rules. Baseline completeness of data fields required to calculate RD-Stage, and calculation of the proportion of cases for whom an RD stage could be assigned, was assessed across each Australian jurisdiction. RD-Stage (Endometrial cancer) was calculated by Victorian Cancer Registry (VCR) medical coders and compared with clinical stage recorded by the patient's treating clinician and captured in the National Gynae-Oncology Registry (NGOR). RESULTS The necessary data completeness level for calculating RD-Stage (Endometrial carcinoma) across various Australian jurisdictions varied from 0 to 89%. Three jurisdictions captured degree of spread of cancer, rendering RD-Stage unable to be calculated. RD-Stage (Endometrial carcinoma) could not be derived for 64/485 (13%) cases and was not captured for 44/485 (9%) cases in NGOR. At stage category level (I, II, III, IV), there was concordance between RD-Stage and NGOR captured stage in 393/410 (96%) of cases (95.8%, Kendall's coefficient = 0.95). CONCLUSION A lack of consistency in data captured by, and data sources reporting to, population-based cancer registries meant that it was not possible to provide national endometrial carcinoma stage data at diagnosis. In a sample of Victorian cases, where surgical pathology was available, there was very good concordance between RD-Stage (Endometrial carcinoma) and clinician-recorded stage data available from NGOR. RD-Stage offers promise in capturing endometrial cancer stage at diagnosis for population epidemiological purposes when it is not provided by health services, but requires more extensive validation.
Collapse
Affiliation(s)
- S M Evans
- Cancer Council Victoria, Melbourne, Australia.
| | - K Ivanova
- Cancer Council Victoria, Melbourne, Australia
| | - R Rome
- Epworth Health Care, Melbourne, Australia
| | - D Cossio
- Cancer Alliance Queensland, Woolloongabba, Australia
| | - Chc Pilgrim
- Central Clinical School, Department of Surgery, The Alfred, Monash University, Melbourne, Australia
| | - J Zalcberg
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - Y Antill
- Monash University, Melbourne, Australia
| | - L Blake
- Cancer Council Victoria, Melbourne, Australia
| | - A Du Guesclin
- Department of Anatomical Pathology, The Alfred, Melbourne, Australia
| | - A Garrett
- Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - D Giffard
- Cancer Alliance Queensland, Woolloongabba, Australia
| | - N Golobic
- Cancer Alliance Queensland, Woolloongabba, Australia
| | - D Moir
- Department of Anatomical Pathology, The Alfred, Melbourne, Australia
| | - S Parikh
- Cancer Council Victoria, Melbourne, Australia
| | - A Parisi
- ACT Cancer Registry Australian Capital Territory Health, Deakin, Australia
| | - K Sanday
- Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - C Shadbolt
- Royal Women's Hospital, Melbourne, Australia
| | - M Smith
- ACT Cancer Registry Australian Capital Territory Health, Deakin, Australia
| | | | - K Williams
- Cancer Council Victoria, Melbourne, Australia
| |
Collapse
|
3
|
Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, Hanson H, Snape K, Kulkarni A, Allen S, Jezdic S, Ferrandino R, Westphalen CB, Castro E, Rodon J, Mateo J, Burghel GJ, Berger MF, Mandelker D, Turnbull C. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol 2023; 34:215-227. [PMID: 36529447 DOI: 10.1016/j.annonc.2022.12.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 12/01/2022] [Accepted: 12/11/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The European Society for Medical Oncology Precision Medicine Working Group (ESMO PMWG) was reconvened to update its 2018/19 recommendations on follow-up of putative germline variants detected on tumour-only sequencing, which were based on an analysis of 17 152 cancers. METHODS We analysed an expanded dataset including 49 264 paired tumour-normal samples. We applied filters to tumour-detected variants based on variant allele frequency, predicted pathogenicity and population variant frequency. For 58 cancer-susceptibility genes, we then examined the proportion of filtered tumour-detected variants of true germline origin [germline conversion rate (GCR)]. We conducted subanalyses based on the age of cancer diagnosis, specific tumour types and 'on-tumour' status (established tumour-gene association). RESULTS Analysis of 45 472 nonhypermutated solid malignancy tumour samples yielded 21 351 filtered tumour-detected variants of which 3515 were of true germline origin. 3.1% of true germline pathogenic variants were absent from the filtered tumour-detected variants. For genes such as BRCA1, BRCA2 and PALB2, the GCR in filtered tumour-detected variants was >80%; conversely for TP53, APC and STK11 this GCR was <2%. CONCLUSION Strategic germline-focused analysis can prioritise a subset of tumour-detected variants for which germline follow-up will produce the highest yield of most actionable true germline variants. We present updated recommendations around germline follow-up of tumour-only sequencing including (i) revision to 5% for the minimum per-gene GCR, (ii) inclusion of actionable intermediate penetrance genes ATM and CHEK2, (iii) definition of a set of seven 'most actionable' cancer-susceptibility genes (BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6 and RET) in which germline follow-up is recommended regardless of tumour type.
Collapse
Affiliation(s)
- Z Kuzbari
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
| | - C Bandlamudi
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - C Loveday
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. https://twitter.com/LovedayChey
| | - A Garrett
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. https://twitter.com/DrAliceGarrett
| | - M Mehine
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - A George
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK
| | - H Hanson
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; South West Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, UK
| | - K Snape
- South West Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, UK. https://twitter.com/genetikos
| | - A Kulkarni
- South East Thames Regional Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London, UK. https://twitter.com/Anju__Kulkarni
| | - S Allen
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
| | - S Jezdic
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| | - R Ferrandino
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| | - C B Westphalen
- Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU) University Hospital, LMU Munich, Munich, Germany
| | - E Castro
- Genitourinary Cancers Translational Research Group, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain. https://twitter.com/Ecastromarcos
| | - J Rodon
- Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - J Mateo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona; Vall d'Hebron University Hospital, Barcelona, Spain
| | - G J Burghel
- North West Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, UK. https://twitter.com/BurghelG
| | - M F Berger
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - D Mandelker
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - C Turnbull
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
| |
Collapse
|
4
|
Loveday C, Garrett A, Law P, Hanks S, Poyastro-Pearson E, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Walker L, Eccles D, Evans DG, Snape K, Hanson H, Houlston RS, Turnbull C. Analysis of rare disruptive germline mutations in 2,135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes. Ann Oncol 2022; 33:1318-1327. [PMID: 36122798 DOI: 10.1016/j.annonc.2022.09.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 08/15/2022] [Accepted: 09/01/2022] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Breast cancer has a significant heritable basis, of which approximately 60% remains unexplained. Testing for BRCA1/BRCA2 offers useful discrimination of breast cancer risk within families, and identification of additional breast cancer susceptibility genes could offer clinical utility. PATIENTS AND METHODS We included 2,135 invasive breast cancer cases recruited via the BOCS study, a retrospective UK study of familial breast cancer. ELIGIBILITY CRITERIA female, BRCA-negative, white European ethnicity, and one of: i) breast cancer family history, ii) bilateral disease, iii) young age of onset (<30 years), iv) concomitant ovarian cancer. We undertook exome sequencing of cases and performed gene-level burden testing of rare damaging variants against those from 51,377 ethnicity-matched population controls from gnomAD. RESULTS 159/2135 (7.4%) cases had a qualifying variant in an established breast cancer susceptibility gene, with minimal evidence of signal in other cancer susceptibility genes. Known breast cancer susceptibility genes PALB2, CHEK2 and ATM were the only genes to retain statistical significance after correcting for multiple testing. Due to the enrichment of hereditary cases in the series, we had good power (>80%) to detect a gene of BRCA1-like risk (odds ratio = 10.6) down to a population minor allele frequency of 4.6 x 10-5 (1 in 10,799, less than one tenth that of BRCA1)and of PALB2-like risk (odds ratio = 5.0) down to a population minor allele frequency of 2.8 x 10-4 (1 in 1,779, less than half that of PALB2). Power was lower for identification of novel moderate penetrance genes (odds ratio = 2-3) like CHEK2 and ATM. CONCLUSIONS This is the largest case-control whole-exome analysis of enriched breast cancer published to date. Whilst additional breast cancer susceptibility genes likely exist, those of high penetrance are likely to be of very low mutational frequency. Contention exists regarding the clinical utility of such genes.
Collapse
Affiliation(s)
- C Loveday
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - A Garrett
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - P Law
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - S Hanks
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - E Poyastro-Pearson
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - J W Adlard
- Yorkshire Regional Genetics Service, St James's University Hospital, Leeds, UK
| | - J Barwell
- Leicestershire Genetics Centre, University Hospitals of Leicester National Health Service (NHS) Trust, Leicester, UK
| | - J Berg
- Division of Medical Sciences, Human Genetics, University of Dundee, Dundee, UK
| | - A F Brady
- North West Thames Regional Genetics Service, Kennedy Galton Centre, London, UK
| | - C Brewer
- Peninsula Regional Genetics Service, Royal Devon & Exeter Hospital, Exeter, UK
| | - C Chapman
- West Midlands Regional Genetics Service, Birmingham Women's Hospital, Birmingham, UK
| | - J Cook
- Sheffield Regional Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK
| | - R Davidson
- West of Scotland Regional Genetics Service, Ferguson Smith Centre for Clinical Genetics, Glasgow, UK
| | - A Donaldson
- South Western Regional Genetics Service, University Hospitals of Bristol NHS Foundation Trust, Bristol, UK
| | - F Douglas
- Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - L Greenhalgh
- Cheshire and Merseyside Clinical Genetics Service, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - A Henderson
- Northern Genetics Service (Cumbria), Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
| | - L Izatt
- South East Thames Regional Genetics Service, Guy's and St. Thomas NHS Foundation Trust, London, UK
| | - A Kumar
- North East Thames Regional Genetics Service, Great Ormond St. Hospital, London, UK
| | - F Lalloo
- University Department of Medical Genetics & Regional Genetics Service, St. Mary's Hospital, Manchester, UK
| | - Z Miedzybrodzka
- University of Aberdeen and North of Scotland Clinical Genetics Service, Aberdeen Royal Infirmary, Aberdeen, UK
| | - P J Morrison
- Belfast Health and Social Care (HSC) Trust & Department of Medical Genetics, Northern Ireland Regional Genetics Service, Queen's University Belfast, Belfast, UK
| | - J Paterson
- East Anglian Regional Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - M Porteous
- South East of Scotland Clinical Genetics Service, Western General Hospital, Edinburgh, UK
| | - M T Rogers
- All Wales Medical Genetics Service, University Hospital of Wales, Cardiff, UK
| | - L Walker
- Oxford Regional Genetics Service, Oxford Radcliffe Hospitals NHS Trust, Oxford, UK
| | -
- Individual collaborators and their affiliations are listed in the Appendix
| | - D Eccles
- Faculty of Medicine, University of Southampton, Southampton University Hospitals NHS Trust, Southampton, UK
| | - D G Evans
- University Department of Medical Genetics & Regional Genetics Service, St. Mary's Hospital, Manchester, UK
| | - K Snape
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.; South West Thames Regional Genetics Service, St. George's Hospital, London, UK
| | - H Hanson
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.; South West Thames Regional Genetics Service, St. George's Hospital, London, UK
| | - R S Houlston
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - C Turnbull
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.; Royal Marsden NHS Foundation Hospital, London, UK.
| |
Collapse
|
5
|
Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, Nicol DL, Jhanji S, Boyce SA, Gronthoud F, Ward P, Handy JM, Yousaf N, Larkin J, Suh YE, Scott S, Pharoah PDP, Swanton C, Abbosh C, Williams M, Lyratzopoulos G, Houlston R, Turnbull C. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 2020; 31:1065-1074. [PMID: 32442581 PMCID: PMC7237184 DOI: 10.1016/j.annonc.2020.05.009] [Citation(s) in RCA: 355] [Impact Index Per Article: 88.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 05/07/2020] [Accepted: 05/10/2020] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term survival. PATIENTS AND METHODS We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of 3 and 6 months and periods of disruption of 1 and 2 years. Using health care resource costing, we contextualise attributable lives saved and life-years gained (LYGs) from cancer surgery to equivalent volumes of COVID-19 hospitalisations. RESULTS Per year, 94 912 resections for major cancers result in 80 406 long-term survivors and 1 717 051 LYGs. Per-patient delay of 3/6 months would cause attributable death of 4755/10 760 of these individuals with loss of 92 214/208 275 life-years, respectively. For cancer surgery, average LYGs per patient are 18.1 under standard conditions and 17.1/15.9 with a delay of 3/6 months (an average loss of 0.97/2.19 LYGs per patient), respectively. Taking into account health care resource units (HCRUs), surgery results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of 3/6 months. For 94 912 hospital COVID-19 admissions, there are 482 022 LYGs requiring 1 052 949 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs. CONCLUSIONS Modest delays in surgery for cancer incur significant impact on survival. Delay of 3/6 months in surgery for incident cancers would mitigate 19%/43% of LYGs, respectively, by hospitalisation of an equivalent volume of admissions for community-acquired COVID-19. This rises to 26%/59%, respectively, when considering RALYGs. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued.
Collapse
Affiliation(s)
- A Sud
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - M E Jones
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - J Broggio
- National Cancer Registration and Analysis Service, Public Health England, Wellington House, London
| | - C Loveday
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - B Torr
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - A Garrett
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - D L Nicol
- Urology Unit, Royal Marsden NHS Foundation Trust, London
| | - S Jhanji
- Department of Anaesthesia, Perioperative Medicine and Critical Care, Royal Marsden NHS Foundation Trust, London; Division of Cancer Biology, Institute of Cancer Research, London
| | - S A Boyce
- Department of Colorectal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford
| | - F Gronthoud
- Department of Microbiology, Royal Marsden NHS Foundation Trust, London
| | - P Ward
- Department of Anaesthesia, Perioperative Medicine and Critical Care, Royal Marsden NHS Foundation Trust, London
| | - J M Handy
- Department of Anaesthesia, Perioperative Medicine and Critical Care, Royal Marsden NHS Foundation Trust, London
| | | | - J Larkin
- Skin and Renal Unit, Royal Marsden NHS Foundation Trust, London; Division of Clinical Studies, Institute of Cancer Research, London
| | - Y-E Suh
- Department of Clinical Oncology, Royal Marsden NHS Foundation Trust, London
| | - S Scott
- RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust, London
| | - P D P Pharoah
- Department of Public Health and Primary Care, University of Cambridge, Cambridge
| | - C Swanton
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London; Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London
| | - C Abbosh
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London; Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London
| | - M Williams
- Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London; Computational Oncology Group, Imperial College London, London
| | - G Lyratzopoulos
- National Cancer Registration and Analysis Service, Public Health England, Wellington House, London; Epidemiology of Cancer Healthcare and Outcomes (ECHO) Group, University College London, London
| | - R Houlston
- Division of Genetics and Epidemiology, Institute of Cancer Research, London; Department of Clinical Genetics, Royal Marsden NHS Foundation Trust, London, UK
| | - C Turnbull
- Division of Genetics and Epidemiology, Institute of Cancer Research, London; National Cancer Registration and Analysis Service, Public Health England, Wellington House, London; Department of Clinical Genetics, Royal Marsden NHS Foundation Trust, London, UK.
| |
Collapse
|
6
|
Struss W, Garrett A, Hamer K, Marsh C, Chedgy E, Dudderidge T, Somani B, Dyer J. Patient triggered follow up (PTFU) for prostate cancer patients post radiotherapy and radical prostatectomy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32713-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
7
|
Turnbull AK, Martinez-Perez C, Mok S, Tanioka M, Fernando A, Renshaw L, Keys J, Wheless A, Garrett A, Parker J, He X, Sims AH, Carey LA, Perou CM, Dixon JM. Abstract P5-04-27: Investigating the incidence of ESR1 gene amplification in breast cancers resistant to multiple endocrine agents. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-04-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Around 70% of all breast cancers (BCs) are estrogen receptor positive (ER+), but some do not respond to endocrine therapy (ET) and many eventually develop resistance. ESR amplification (ESRA) linked to an increase in ESR1 gene expression is known to occur in some cancers that are endocrine resistant. However, the incidence of ESRA has been the object of debate and its clinical significance remains unclear. This study aimed to investigate the incidence of ESRA in BCs resistant to multiple sequential ETs and optimise a fluorescence in-situ hybridisation (FISH) methodology to robustly detect ESRA.
Methods: Two unique cohorts have been studied:
(A) 20 post-menopausal women with ER+ BC with acquired resistance to letrozole, subsequently treated with up to 4 different lines of ET. Serial RNA and DNA from 3-5 cancer samples per patient (58 samples from 20 patients) were analysed by Ribo0-RNAseq and DNA exome sequencing;
(B) 18 post-menopausal women who developed ER+ BC recurrences on 1st line adjuvant letrozole, then on 2nd line tamoxifen and subsequently on 3rd line exemestane. Tissues were collected at the time of each surgery.
We have optimised a FISH method to assess ESRA in these tissues.
Results: In cohort A, 6/20 patients developed ESR1 gene amplification (ESRA) at some point during treatment. In 5 of these cases, ESRA was only found while on 2nd or 3rd line exemestane but was not present on acquired resistance to previous letrozole or tamoxifen. 1 patient had ESRA at the time of first recurrence on letrozole.
The FISH method showed concordance with the genomic analysis. This suggests that ESRA may be associated with BCs that are treated with and then become resistant to exemestane.
ESRA is also evident in samples from Cohort B, which includes 18 exemestane resistant cases. The complete analysis is ongoing.
Conclusions:
· ESRA can be seen in ER+ recurrent BCs.
· ESRA may be associated with BCs treated with 2nd or 3rd line exemestane.
· The frequency of ESRA in endocrine and exemestane resistance can now be ascertained using an optimised FISH-based method, which is more cost-effective than alternative genomic and biochemical methods.
Citation Format: Turnbull AK, Martinez-Perez C, Mok S, Tanioka M, Fernando A, Renshaw L, Keys J, Wheless A, Garrett A, Parker J, He X, Sims AH, Carey LA, Perou CM, Dixon JM. Investigating the incidence of ESR1 gene amplification in breast cancers resistant to multiple endocrine agents [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-27.
Collapse
Affiliation(s)
- AK Turnbull
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - C Martinez-Perez
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - S Mok
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - M Tanioka
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - A Fernando
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - L Renshaw
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - J Keys
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - A Wheless
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - A Garrett
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - J Parker
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - X He
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - AH Sims
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - LA Carey
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - CM Perou
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - JM Dixon
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Arab Emirates; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| |
Collapse
|
8
|
Martinez-Perez C, Turnbull AK, Tanioka M, Fernando A, Renshaw L, Keys J, Wheless A, Garrett A, Parker J, He X, Sims AH, Carey LA, Perou CM, Dixon JM. Abstract P5-04-14: Tracking ESR1 mutation clonal evolution in breast cancer using in situ mutation detection. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-04-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Approximately 70% of breast cancers (BCs) are estrogen receptor positive (ER+). Not all ER+ cancers respond to endocrine therapy (ET) and many eventually develop acquired resistance. Next-generation sequencing (NGS) has shown ESR1 mutations (ESRMs) are present in 10-50% of recurrent/metastatic cancers treated with aromatase inhibitors (AIs). Many of these mutations are located in the ligand-binding domain of ER, so they can lead to constitutive activation. This suggests ESRMs are a major mechanism of acquired resistance to endocrine therapy (ET) and numerous studies have shown a link between ESRMs and reduced sensitivity to 2nd line ET. The aim of this project was to investigate the incidence and clonal evolution of common ESRMs in BCs resistant to multiple sequential ETs using NGS, as well as novel PCR and in situ mutation detection methods.
Methods: We have optimised an allele-specific real-time PCR (rtPCR) assay and an in situ mutation detection method (ER-ISMD) for the assessment of ESRMs. Both have been designed to identify a missense gain-of-function D538G mutation with a single nucleotide-resolution in formalin-fixed paraffin-embedded (FFPE) BC tissues.
Two unique cohorts have been studied:
(A) 20 post-menopausal women (PMW) with ER+ BC who acquired resistance to letrozole and were treated with up to 4 subsequent lines of ET. Serial RNA and DNA from 3-5 cancer samples per patient (58 samples from 20 patients) were analysed by Ribo0-RNAseq, DNA exome sequencing, rtPCR and ER-ISMD.
(B) 150 PMW with ER+ BC who developed local (n=79), lymph node (n=59) or distant (n=12) recurrences on 1st line adjuvant letrozole, anastrozole or tamoxifen. Of these, 48 patients developed subsequent recurrences on 2nd line ET. Tissue samples from each recurrence and matched primary BC were collected.
Results: In cohort A, 5/20 patients (20%) had expansion of a D538G ESR1 mutation clone at time of resistance 1st line ET (3:letrozole, 1:anastrozole, 1:tamoxifen). The mutant allele frequency (MAF) increased further in the 4 BCs treated with 2nd line ET (2:tamoxifen, 2:exemestane) and further still in the 1 BC who received 3rd line exemestane. 0/6 patients with ESRM responded to subsequent ET. Allele-specific rtPCR and ER-ISMD have been used to validate these findings and also identified low frequency ESRM clones in the sequential samples prior to the development of clinical resistance, that were not reported by NGS. Both methods have also been applied to screen tissues from patients in cohort B, where ESRMs have also been identified in recurrent samples. Complete analysis is currently ongoing.
Conclusions:
· ESRMs develop and expand in some BCs as a mechanism for acquired resistance to ET and are associated with a lack of response to subsequent standard ETs.
· Allele-specific rtPCR can detect ESRMs and is more cost-effective and easier to use than NGS for ER mutation analysis.
· Some ESRMs predate clinical resistance.
· ER-ISMD is a novel approach that allows for identification and visualisation of the distribution of mutant clones in morphologically intact FFPE tissue.
· ER-ISMD has the potential to become a clinically useful tool to help direct the use of 2nd line ET in routine care.
Citation Format: Martinez-Perez C, Turnbull AK, Tanioka M, Fernando A, Renshaw L, Keys J, Wheless A, Garrett A, Parker J, He X, Sims AH, Carey LA, Perou CM, Dixon JM. Tracking ESR1 mutation clonal evolution in breast cancer using in situ mutation detection [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-14.
Collapse
Affiliation(s)
- C Martinez-Perez
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - AK Turnbull
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - M Tanioka
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - A Fernando
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - L Renshaw
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - J Keys
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - A Wheless
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - A Garrett
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - J Parker
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - X He
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - AH Sims
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - LA Carey
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - CM Perou
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - JM Dixon
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| |
Collapse
|
9
|
Malfertheiner M, Suen J, Garrett A, Fraser J. Evaluation eines neuen Faktor XIIa Antikörpers – CSL312 – zur Antikoagulation bei Extrakorporaler Membranoxygenierung. Pneumologie 2018. [DOI: 10.1055/s-0037-1619308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M Malfertheiner
- Abteilung für Innere Medizin II, Universitätsklinikum Regensburg
| | - J Suen
- Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia
| | - A Garrett
- Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia
| | - J Fraser
- Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia
| |
Collapse
|
10
|
Dixon JM, Turnbull AK, Tanioka M, Wheless A, Garrett A, Martinez-Perez C, Parker J, He X, Sims AH, Thomas JS, Carey LA, Perou CM. Abstract P4-03-01: Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER+ breast cancers. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-03-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: 70% of all breast cancers (BCs) are ER+. Not all ER+ cancers respond to endocrine therapy (ET) and many eventually develop resistance. The aim was to perform in-depth genomic analysis of both primary resistant BCs, that do not respond to ET, and cancers which progress (>40% increase in size) after an initial response as they acquire resistance (AQR) to ET.
Methods: A unique series of 48 post-menopausal women with ER+ BC received neoadjuvant ET using letrozole (L) or anastrozole (A) (mean treatment duration 17 months, range 3-67). 13/48 received up to 4 lines of ET.
12/48 responded to A or L, 16/48 had primary resistance and 20/48 had AQR.
Of 20 with AQR, 13 had 2nd line ET with A or tamoxifen (T). 6 had 3rd line ET with exemestane (E) and 1 had 4th line megestrol acetate (MA). Serial RNA & DNA from 3-5 cancer samples/patient (226 samples) had Ribo0-RNAseq, DNA exome sequencing and somatic mutation detection using UNCeqR. We have data so far on 29 patients: 5 responders, 4 with primary resistance and 20 AQR, the full cohort will be complete shortly.
Results:
ESR1 Mutations (ESRM): 1/5 responders had an ESRM (E380Q) at diagnosis. This clone disappeared with response to L. 5/20 patients with AQR (25%) had clonal expansion of an ESRM during 1st line ET (L:4, A:1). 4 had a chr6:152419926[lowbar]A:G (D538G) ESRM and 1 had a novel ESRM. Of the 5 with ESRM acquired during 1st line ET, the mutant allele fraction (MAF) increased further in the 4 who had 2nd ET (3:T, 1:E) and increased further for the 2 who had 3rd line E.
ESR1 Amplification (ESRA):
5 patients developed ESRA. 3/5 developed ESRA on 2nd or 3rd line E that was not present on AQR to 1st line L or A and 2nd line T. The other 2 developed ESRA on L. 2/5 with ESRA had concomitant CYP19A1 amplification. One patient with ESRA that developed on 3rd line E subsequently responded to MA. No patients with primary resistance to 1st line ET had an ESRM or ESRA.
PIK3CA mutations (PIK3M): 5/20 with AQR had PIK3M (25%). 3/7 had PIK3M at diagnosis and in 3 MAF increased between 1st and 2nd line ET. 2/7 developed PIK3M when resistant to 2nd line ET, 1 of the 2 had ESRA. 2 patients responsive to L had PIK3M at diagnosis and MAF decreased with therapy.
Other Mutations: Unique mutations with limited commonality developed and new clones expanded in the remaining cancers during primary and acquired resistance. Clonality analysis of AQR samples to different ETs showed proliferation of specific clones, characterised by novel sets of mutations, which typically became the dominant clone at the time of resistance to a particular agent.
Summary: 13/20 with acquired resistance had ESRM, ESRA, or PIK3M in resistant tumours: 1 had all 3, 2 ERSM + ESRA, 1 ERSA + PIK3CA, 4 ESRM only, 2 ESRA only and 3 had PIK3M only.
Conclusions:
• Endocrine resistance is complex
• ESRM or ESRA is uncommon at diagnosis and does not explain primary ET resistance
• ESRM (in particular the D538G mutation) occurs in one-third of patients with acquired resistance. 2nd line ET results in clonal selection and expansion of ESRM cells. Assessing recurrences for ESRM by in situ detection has clinical utility
• ESRA is only seen in heavily ET-pre-treated tumours, with its significance being unknown.
Citation Format: Dixon JM, Turnbull AK, Tanioka M, Wheless A, Garrett A, Martinez-Perez C, Parker J, He X, Sims AH, Thomas JS, Carey LA, Perou CM. Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER+ breast cancers [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-03-01.
Collapse
Affiliation(s)
- JM Dixon
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - AK Turnbull
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - M Tanioka
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - A Wheless
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - A Garrett
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - C Martinez-Perez
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - J Parker
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - X He
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - AH Sims
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - JS Thomas
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - LA Carey
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| | - CM Perou
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom; Lineberger Comprehensive Cancer Cente, University of North Carolina, Chapel Hill, NC; Western General Hospital, Edinburgh, United Kingdom
| |
Collapse
|
11
|
Tang A, Hong I, Boddington L, Reynolds J, Garrett A, Etherington S, Rodger J. P135 Intermittent theta burst increases action potential threshold and spike firing in cortical layer 5 pyramidal neurons. Clin Neurophysiol 2017. [DOI: 10.1016/j.clinph.2016.10.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Guest J, Weidlich D, Singh H, La Fontaine J, Garrett A, Abularrage C, Waycaster C. Cost-effectiveness of using adjunctive porcine small intestine submucosa tri-layer matrix compared with standard care in managing diabetic foot ulcers in the US. J Wound Care 2017; 26:S12-S24. [DOI: 10.12968/jowc.2017.26.sup1.s12] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- J.F. Guest
- Director of Catalyst, Visiting Professor of Health Economics, Catalyst Health Economics Consultants, Northwood, Middlesex, UK; and Faculty of Life Sciences and Medicine, King's College, London, UK
| | - D. Weidlich
- Health Economist, Catalyst Health Economics Consultants, Northwood, Middlesex, UK
| | - H. Singh
- Health Economist, Catalyst Health Economics Consultants, Northwood, Middlesex, UK
| | - J. La Fontaine
- Professor of Plastic Surgery; University of Texas, Southwestern Medical Center, Dallas, TX, US
| | - A. Garrett
- Assistant Professor, Ben Hogan Bone & Joint Clinic, Fort Worth, TX, US
| | - C.J. Abularrage
- Associate Professor of Surgery, Director, Multidisciplinary Diabetic Foot & Wound Clinic, Diabetic Foot & Wound Clinic, The Johns Hopkins Hospital, Baltimore, MD, US
| | - C.R. Waycaster
- Director, Health Economics, Smith & Nephew Biotherapeutics, Fort Worth, TX, US
| |
Collapse
|
13
|
Garrett A, Gupta S, Reiss AL, Waring J, Sudheimer K, Anker L, Sosa N, Hallmayer JF, O'Hara R. Impact of 5-HTTLPR on hippocampal subregional activation in older adults. Transl Psychiatry 2015; 5:e639. [PMID: 26393485 PMCID: PMC5068801 DOI: 10.1038/tp.2015.131] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Accepted: 04/23/2015] [Indexed: 11/29/2022] Open
Abstract
Studies have shown that a functional polymorphism of the serotonin transporter gene (5-HTTLPR) impacts performance on memory-related tasks and the hippocampal structures that subserve these tasks. The short (s) allele of 5-HTTLPR has been linked to greater susceptibility for impaired memory and smaller hippocampal volume compared to the long allele (l). However, previous studies have not examined the associations between 5-HTTLPR allele and activation in subregions of the hippocampus. In this study, we used functional magnetic resonance imaging (fMRI) to measure activation in hippocampal and temporal lobe subregions in 36 elderly non-clinical participants performing a face-name encoding and recognition task. Although there were no significant differences in task performance between s allele carriers and l homozygotes, right CA1 and right parahippocampal activation during recognition errors was significantly greater in individuals bearing the s allele. In an exploratory analysis, we determined that these effects were more pronounced in s allele carriers with the apolipoprotein ɛ4 allele. Our results suggest that older individuals with the s allele inefficiently allocate neural resources while making errors in recognizing face-name associations, which could negatively impact memory performance during more challenging tasks.
Collapse
Affiliation(s)
- A Garrett
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA,Center for Interdisciplinary Brain Sciences Research, Stanford University School of Medicine, Stanford, CA, USA
| | - S Gupta
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
| | - A L Reiss
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA,Center for Interdisciplinary Brain Sciences Research, Stanford University School of Medicine, Stanford, CA, USA
| | - J Waring
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA,Sierra Pacific Mental Illness, Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - K Sudheimer
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA,Sierra Pacific Mental Illness, Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - L Anker
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA,Sierra Pacific Mental Illness, Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - N Sosa
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
| | - J F Hallmayer
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA,Sierra Pacific Mental Illness, Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - R O'Hara
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA,Sierra Pacific Mental Illness, Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, USA,Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305-5485, USA. E-mail:
| |
Collapse
|
14
|
Hackethal A, Brennan D, Rao A, Land R, Obermair A, Nicklin J, Garrett A, Nascimento M, Crandon A, Perrin L, Chetty N. Consideration for safe and effective gynaecological laparoscopy in the obese patient. Arch Gynecol Obstet 2014; 292:135-41. [DOI: 10.1007/s00404-014-3600-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2014] [Accepted: 12/11/2014] [Indexed: 12/22/2022]
|
15
|
Garrett A, Strauss C, Saha S. National survey of ICUs in the UK: discharging patients with tracheostomies. Crit Care 2014. [PMCID: PMC4069463 DOI: 10.1186/cc13515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
|
16
|
Kondalsamy-Chennakesavan S, Johnson S, Nicklin J, Land R, Garrett A, Obermair A. Charlson's index: A validation study to predict surgical adverse events in gynecologic oncology. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Arnow B, Millheiser L, Garrett A, Lake Polan M, Glover G, Hill K, Lightbody A, Watson C, Banner L, Smart T, Buchanan T, Desmond J. Women with hypoactive sexual desire disorder compared to normal females: A functional magnetic resonance imaging study. Neuroscience 2009; 158:484-502. [DOI: 10.1016/j.neuroscience.2008.09.044] [Citation(s) in RCA: 123] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2008] [Revised: 08/21/2008] [Accepted: 09/12/2008] [Indexed: 01/23/2023]
|
18
|
Durrani AA, Garrett A, Johnson RA, Sood SK, Tyman JH. EARLY EXPERIMENTATION IN THE LIQUID CHROMATOGRAPHY OF NATURAL AND SYNTHETIC PRODUCTS. J LIQ CHROMATOGR R T 2007. [DOI: 10.1081/jlc-120005703] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- A. A. Durrani
- a Department of Chemistry , Brunel University , Uxbridge , Middlesex , UK
| | - A. Garrett
- a Department of Chemistry , Brunel University , Uxbridge , Middlesex , UK
| | - R. A. Johnson
- a Department of Chemistry , Brunel University , Uxbridge , Middlesex , UK
| | - S. K. Sood
- a Department of Chemistry , Brunel University , Uxbridge , Middlesex , UK
| | - J. H.P. Tyman
- b Department of Chemistry , Brunel University , Uxbridge , Middlesex , UK
| |
Collapse
|
19
|
|
20
|
Abstract
OBJECTIVE The aim of this study was to characterize endometrial cancer in women 40 years of age and younger, with special attention toward body-mass index (BMI). METHODS A retrospective review of women age 40 and under with endometrial cancer was performed. Patients were identified via tumor registry data as well as a search of pathology department diagnoses over the dates 1980-1998. Data were abstracted regarding tumor grade and histology, stage, treatment, smoking, use of oral contraceptives, BMI, medical and family history, parity, and survival. Data were also collected with regard to uterine conservation and pregnancies following endometrial cancer diagnoses. RESULTS Ninety-five patients were identified. The age range was 24-40 years (median 37) with BMI ranging from 17.5 to 63.6 (median 28.4). Forty-eight patients (52%) were not obese, with BMI < 30. Seventy-six patients (80%) had stage I disease and 60 patients (63%) had grade 1 disease. All but 4 patients had endometrioid histology. Women with BMI < 25 were more likely to have advanced disease (P = 0.04) and more likely to have high-risk histology (P = 0.02). Of the 4 patients with high-risk histology (clear cell or serous papillary), all had BMI < 25. Twelve patients were treated medically rather than surgically, and 4 patients achieved pregnancy, with 5 live births. CONCLUSION Women under 40 who are not obese are at higher risk of both advanced disease and high-risk histology. Further study at the molecular and genetic level is ongoing in our laboratory to determine whether the mechanism of disease is different in slender woman.
Collapse
Affiliation(s)
- L R Duska
- Vincent Gynecology Service, Division of Gynecologic Oncology, Boston, Massachusetts 02114, USA.
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
Symptomatic sinus bradycardia, due to either sick sinus syndrome or vagotonia, can be familial, affecting several members of a family. We report an 18-year-old male patient with palpitations and limited exercise capacity who was noted to have severe sinus bradycardia. His resting heart rate was 40/min, with normal PR and corrected QT intervals, and sinus pauses up to 6 seconds during sleep. Exercise treadmill test and pharmacologic autonomic blockade during electrophysiologic studies abolished the bradycardia, suggestive of vagotonia rather than intrinsic sinus node dysfunction. This patient's father and a female cousin had a similar clinical history but associated with syncope and severe sinus bradycardia. The mode of transmission appeared to be autosomal dominant. All three have permanent demand pacemakers implanted and are asymptomatic.
Collapse
Affiliation(s)
- A V Mehta
- Department of Pediatrics, James H. Quillen College of Medicine, East Tennessee State University, Johnson City 37604, USA
| | | | | |
Collapse
|
22
|
Gifford BD, Garrett A, Hofmann L. Clinical problem-solving: we blew it. N Engl J Med 1995; 333:520-1. [PMID: 7623889 DOI: 10.1056/nejm199508243330813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
23
|
Cohen IK, Crossland MC, Garrett A, Diegelmann RF. Topical application of epidermal growth factor onto partial-thickness wounds in human volunteers does not enhance reepithelialization. Plast Reconstr Surg 1995; 96:251-4. [PMID: 7624397 DOI: 10.1097/00006534-199508000-00001] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Recent reports have suggested that human epidermal growth factor will accelerate the healing of corneal wounds and donor sites of burned patients undergoing split-thickness skin grafts. In one report using human epidermal growth factor in a silver sulfadiazine cream, these data were gathered from patients of various ages who had various depths of donor sites and degrees of burn. Therefore, despite the fact that these data were prospective, randomized, and double-blinded, we questioned the validity of the study. To test the hypothesis that topical application of human epidermal growth factor will enhance the healing of partial-thickness wounds, we utilized healthy volunteers (n = 17) and created bilateral split-thickness skin wounds (4 cm2) of the same depth (0.014 in) on each flank and then studied time until total epithelialization occurred. One side was treated with silver sulfadiazine as a control and the opposite side with silver sulfadiazine and human epidermal growth factor. There was no significant difference in the healing times between the human epidermal growth factor-treated sites and the silver sulfadiazine cream controls.
Collapse
Affiliation(s)
- I K Cohen
- Wound Healing Center, Medical College of Virginia and Virginia Commonwealth University, Richmond, USA
| | | | | | | |
Collapse
|
24
|
Crooke ST, Grillone LR, Tendolkar A, Garrett A, Fratkin MJ, Leeds J, Barr WH. A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharmacol Ther 1994; 56:641-6. [PMID: 7995006 DOI: 10.1038/clpt.1994.189] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Afovirsen sodium is a 20-mer phosphorothioate oligonucleotide designed to be complementary to the messenger ribonucleic acid sequence for the translation initiation codon of the E2 protein vital to replication of human papillomaviruses types 6 and 11. 14C-Labeled afovirsen was given as a single-dose intradermal injection in each of four warts of five patients to determine the time-dependent changes in concentration of intact afovirsen in genital warts and to determine the systemic absorption and elimination of radiolabeled compound. Intact afovirsen in genital warts was determined by high pressure liquid chromatography analysis of protease K digested extracts. Intact afovirsen was present in wart tissue for at least 72 hours at concentrations several times in excess of the estimated minimal inhibitory concentration of 1 mumol/L. Absorption of radiolabeled afovirsen from the injection site was rapid, with a peak plasma concentration achieved within 1 hour. Clearance of afovirsen was primarily attributable to slow metabolism, with about 30% of the radiolabel eliminated as 14C-CO2 in expired air over a 6-day period after dosing. Radioactivity eliminated in urine represented metabolites of afovirsen. From the clinical pharmacokinetic data presented here and from previously published pharmacokinetic data in rats, the disposition of afovirsen in humans appears to be relatively similar to that in rats. These data suggest that once or twice weekly dosing regimen in the clinic may be appropriate.
Collapse
Affiliation(s)
- S T Crooke
- Isis Pharmaceuticals, Carlsbad Research Center, CA 92008
| | | | | | | | | | | | | |
Collapse
|
25
|
Smith-Rooker JL, Garrett A, Hodges LC. Case management of the patient with pituitary tumor. Medsurg Nurs 1993; 2:265-274. [PMID: 7688634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Many medical-surgical nurse case managers will care for patients with pituitary tumors at some point in their careers. These patients present multiple challenges throughout their courses of treatment. Using astute assessment and intervention skills, the nurse case manager can positively influence the outcomes of therapy for these patients, whether they are in the diagnostic, treatment, or follow-up phase of care. Nursing management can indeed make a difference in the costs of money, time, and functional disabilities experienced by patients with pituitary tumors.
Collapse
|
26
|
Singh SP, McAvoy J, Garrett A, Egan AF, Rogers PJ. Pathways of pyruvate metabolism and energetics of growth of Brochothrix thermosphacta. World J Microbiol Biotechnol 1993; 9:361-5. [DOI: 10.1007/bf00383081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 01/21/1993] [Accepted: 02/03/1993] [Indexed: 10/26/2022]
|
27
|
Hutcherson S, Garrett A, Venitz J, Kisner D. 197 Double blind, vehicle-controlled rising dose tolerance study of ISIS 2105, a phosphorothioate oligonucleotide for treatment of condyloma acuminatum. Antiviral Res 1993. [DOI: 10.1016/0166-3542(93)90575-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
Abstract
The charts of 100 patients with established diagnoses of glioblastoma multiforme (GBM) provided the data base for a descriptive study of patients' exposure to herbicides. The study focused on place of residence and occupation during the year prior to diagnosis of GBM. Although subjects reported residences in 33 of the 75 counties in Arkansas, more than one-third of the sample came from just 3 counties in which rice, cotton or wood products are produced. These industries were reported as the occupations of almost one-third of the sample for whom occupations involved a risk of herbicide exposure. The findings of this study add to the epidemiological profile of those at risk for GBM and underscore the need for assessment of residence and occupation on a consistent basis when counseling patients and providing health education.
Collapse
|
29
|
Abstract
This retrospective study profiled subjects with glioblastoma multiforme (GBM) who had previously received therapeutic radiation. A chart review was conducted of 100 adult patients diagnosed with GBM and referred to a major medical center in the southwestern United States. Seventeen patients received previous radiation therapy with an average dose of 48.5 Grey (Gy) and an average latency period of 15 years between initial therapy and GBM diagnosis. Of these 17, four white females fit all four attribution criteria for radiation-induced GBM. Two had been treated with radiation for prolactinomas, one for pinealoma and one for squamous cell cancer of the ethmoid sinus. The addition of these four case studies to the previously published descriptions of 80 cases of gliomas, 36 of which were GBM, subsequent to radiation therapy provides additional support for considering therapeutic radiation as a risk factor for GBM development.
Collapse
Affiliation(s)
- L C Hodges
- University of Arkansas for Medical Sciences, College of Nursing, Little Rock 72205
| | | | | | | |
Collapse
|
30
|
Bradham WG, Lewis JV, Sewell DH, Garrett A. Bullet embolus to the ascending aorta following a gunshot wound to the chest. J Tenn Med Assoc 1991; 84:592-3. [PMID: 1805076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- W G Bradham
- Department of Surgery, James H. Quillen College of Medicine, East Tennessee State University, Johnson City
| | | | | | | |
Collapse
|
31
|
Garrett A. Techniques in HIV research edited by Anna Aldovini and Bruce D. Walker, Stockton Press, 1990. £35.00 (xi + 288 pages) ISBN 0 333 53540 5. Trends Biotechnol 1991. [DOI: 10.1016/0167-7799(91)90036-h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Garrett A, Jones G. Maybe the patient has PTA? Aust Nurses J 1990; 19:10-2. [PMID: 2222335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
33
|
Abstract
Although breastfeeding two or more infants requires greater organization and presents a challenge to the family, it may in the long run save time. Fatigue, the greatest deterrent to breastfeeding multiples, is common among all new mothers. It is essential for the nurse to demonstrate all of the potential positions for feeding, to stress adequate nutrition, and to encourage getting help from others so that the mother has time to rest each day. Nurses are in an optimal position for influencing successful breastfeeding for multiple birth parents. The dearth of knowledge about breastfeeding twins or other multiples indicates the need for research in this area.
Collapse
|
34
|
Nickel VL, Perry J, Garrett A, Heppenstall M. The halo. A spinal skeletal traction fixation device. By Vernon L. Nickel, Jacquelin Perry, Alice Garrett, and Malcolm Heppenstall, 1968. Clin Orthop Relat Res 1989:4-11. [PMID: 2912634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
35
|
Affiliation(s)
- J Scally
- Department of Radiodiagnosis, Countess of Chester Hospital
| | | |
Collapse
|
36
|
Abstract
We discontinued anticonvulsant drugs in 92 patients who had been free of seizures during two years of treatment with a single drug. All the patients had epilepsy that had previously been untreated, and had been randomly assigned to receive carbamazepine, phenytoin, or sodium valproate. Thirty-one patients relapsed, and 61 remained free of seizures. The mean duration of the follow-up in the patients remaining free of seizures was 35 months (range, 6 to 62). There was no significant difference between the relapse rate among adults (35 percent) and that among children (31 percent). Our results suggest that the number of seizures a patient had before control was achieved, the number of drugs tried as single-drug therapy, and the type of treatment withdrawn all influenced the outcome. Among the various types of seizures, complex partial seizures with secondary generalization carried the worst prognosis. In comparison, the risk of relapse was 65 percent lower in patients with generalized seizures and 97 percent lower in patients with complex or simple partial seizures in the absence of secondary generalized attacks. Among the four electroencephalographic classes, class 4 (abnormal before treatment and unchanged before withdrawal) carried the worst prognosis. The risk of relapse was 94 to 99 percent lower in patients in the other three electroencephalographic classes. Among the three anticonvulsants, withdrawal of sodium valproate carried the worst prognosis. In comparison, the odds of relapsing were 28 percent lower after withdrawal of phenytoin and 85 percent lower after withdrawal of carbamazepine. We conclude that withdrawal of anticonvulsant medication should be considered in patients free of seizures for two years.
Collapse
Affiliation(s)
- N Callaghan
- Department of Neurology, Cork Regional Hospital, Ireland
| | | | | |
Collapse
|
37
|
Abstract
Multilocular cystic nephroma is an uncommon renal neoplasm which in childhood usually presents as an abdominal mass. The same condition is also described as multilocular kidney and multilocular cystic hamartoma. The clinical presentation, and radiological findings in three cases of multilocular cystic nephroma are described.
Collapse
|
38
|
Reed WW, Patterson JW, Behm FG, Littman B, Garrett A. Malignant histiocytosis presenting with vasculitis and cutaneous erythrophagocytosis. Cutis 1986; 38:63-6. [PMID: 3731873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We report a case of malignant histiocytosis that presented initially as a cutaneous vasculitis without malignant features. A subsequent biopsy specimen of an erythematous skin lesion showed erythrophagocytosis by normal-appearing histiocytes within the subcutis. The recognition of erythrophagocytosis was followed by systemic symptoms and signs of malignant histiocytosis and a rapidly deteriorating clinical course. Possible mechanisms for erythrophagocytosis are discussed, and other diseases associated with this histologic finding are reviewed briefly.
Collapse
|
39
|
Garrett A. Nursing care study: wait, hope and pray. Nurs Mirror 1984; 159:33-4. [PMID: 6382181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
40
|
Garrett A. Nursing Mirror clinical forum. 4. Coronary artery vein graft. Nurs Mirror 1983; 156:vi-viii. [PMID: 6189051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
41
|
Garrett A. Nursing care study: a change of pace. Nurs Mirror 1983; 156:42-3. [PMID: 6560551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
|
42
|
Garrett A. Nursing care study: little boy blue. Nurs Mirror 1982; 155:49-50. [PMID: 6924273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
43
|
Blake R, Martens W, Garrett A, Westendorf D. Estimating probability summation for binocular reaction time data. Percept Psychophys 1980; 27:375-8. [PMID: 7383825 DOI: 10.3758/bf03206129] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
44
|
Garrett A, Manuel D, Vincent C. Conceptual framework. J Nurs Educ 1976; 15:9-21. [PMID: 10357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
45
|
|
46
|
Leahey E, Reyes R, Garrett A, Chu LS. Clinical study of lower-extremity amputees. With emphasis on use of modular-unit prostheses. N Y State J Med 1973; 73:1186-8. [PMID: 4512242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
47
|
Hoffer MM, Garrett A, Brink J, Perry J, Hale W, Nickel VL. The orthopaedic management of brain-injured children. J Bone Joint Surg Am 1971; 53:567-77. [PMID: 4996285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
48
|
Nickel VL, Perry J, Garrett A, Heppenstall M. The halo. A spinal skeletal traction fixation device. J Bone Joint Surg Am 1968; 50:1400-9. [PMID: 5677293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|